Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics.
|June 19, 2013||Intezyne Technologies Expands Its Oncology Pipeline Through Strategic Acquisition of Niiki Pharma|
|May 24, 2012||Niiki Pharma to Present Final Phase I Clinical Data on Anti-Cancer Agent at ASCO|
|April 3, 2012||Niiki Pharma Presents Data on NKP-2235, the First Highly Orally Bioavailable Gallium-Based Anti-Cancer Agent|
|March 28, 2012||Niiki Pharma to Present Preclinical Results, Start Testing Cancer Drug|
|March 23, 2012||Orally Bioavailable Gallium-Based Anti-Cancer Agent|
|March 5, 2012||Niiki Pharma’s NKP-2235 and NKP-1339 Featured in Two Industry Publications|
|February 15, 2012||Niiki Pharma Breaks New Ground with Novel Cancer Therapy: Pharmaceutical International News|